Theranostic nanodevices offering PSMA-targeting for prostate cancer can be helpful, especially if coupled with beta-, alpha-, or Auger-emitting radioisotopes for therapy and positron-emitters for diagnostics. The gene discussed is FOLH1; the disease is prostate cancer.